Skip to main content
Midas Edge

MAXCYTE, INC.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share amounts)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Additional · ​ · Treasury · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Paid-in Capital · ​ ​ ​ · Stock · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balance at January 1, 2025105,711,093​$1,057​$422,047​$—​$(216,853)​$206,251
Stock-based compensation expense—​—​3,039​—​—​3,039
Exercise of stock options​290,993​​3​​380​​—​​—​​383
Vesting of restricted stock units​311,632​​3​​(3)​​—​​—​​—
Net loss—​—​—​—​(10,261)​(10,261)
Balance at March 31, 2025106,313,718​​1,063​​425,463​​—​​(227,114)​​199,412
Stock-based compensation expense​—​​—​​3,514​​—​​—​​3,514
Exercise of stock options18,542​—​20​—​—​20
Vesting of restricted stock units​191,700​​2​​(2)​​—​​—​​—
Issuance of common stock underemployee stock purchase plan​68,179​​1​​133​​—​​—​​134
Net loss—​—​—​—​(12,357)​(12,357)
Balance at June 30, 2025106,592,139​​1,066​​429,128​​—​​(239,471)​​190,723
Stock-based compensation expense​—​​—​​1,954​​—​​—​​1,954
Exercise of stock options​14,442​​—​​14​​—​​—​​14
Vesting of restricted stock units​37,762​​—​​—​​—​​—​​—
Net loss​—​​—​​—​​—​​(12,416)​​(12,416)
Balance at September 30, 2025​106,644,343​$1,066​$431,096​$—​$(251,887)​$180,275
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Additional · ​ · Treasury · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Paid-in Capital · ​ ​ ​ · Stock · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balance at January 1, 2026106,789,618​$1,068​$431,905​$—​$(261,483)​$171,490
Stock-based compensation expense—​—​1,141​—​—​1,141
Exercise of stock options​4,814​​—​​5​​—​​—​​5
Vesting of restricted stock units​327,240​​3​​(3)​​—​​—​​—
Net loss—​—​—​—​(4,750)​(4,750)
Balance at March 31, 2026107,121,672​​1,071​​433,048​​—​​(266,233)​​167,886
Stock-based compensation expense—​—​1,160​—​—​1,160
Exercise of stock options​24,634​​—​​24​​—​​—​​24
Vesting of restricted stock units​262,655​​3​​(3)​​—​​—​​—
Issuance of common stock underemployee stock purchase plan​38,116​​—​​34​​—​​—​​34
Repurchases of common stock​​​​​​​​​​(1,478)​​​​​(1,478)
Net loss—​—​—​—​​(8,874)​(8,874)
Balance at June 30, 2026107,447,077​​1,074​​434,263​​(1,478)​​(275,107)​$158,752
Stock-based compensation expense​—​​—​​963​​—​​—​​963
Vesting of restricted stock units​46,695​​1​​(1)​​—​​—​​—
Exercise of stock options​—​​—​​—​​—​​—​​—
Repurchases of common stock​—​​—​​—​​(4,022)​​—​​(4,022)
Net loss​—​​—​​—​​—​​(4,762)​​(4,762)
Balance at September 30, 2026​107,493,772​$1,075​$435,225​$(5,500)​$(279,869)​$150,931
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.